Optimal Starting Dose of Ponatinib for Chronic Phase Chronic Myeloid Leukemia
Researchers evaluated the benefit-risk ratio across 3 ponatinib starting doses in patients with chronic phase chronic myeloid leukemia.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Nilotinib Treatment May Cause Growth Deceleration in Children With Chronic Myelogenous Leukemia
Researchers sought to determine whether pediatric patients with CML may have attenuated growth when receiving treatment with nilotinib.
Study Identifies Factors Linked With CNS Relapse in Pediatric Patients With Acute Lymphoblastic Leukemia
Researchers sought to determine the risk factors of CNS relapse in pediatric patients with ALL.
Poor Prognosis Seen for Patients With B-Cell Acute Lymphoblastic Leukemia Progression After CAR-T Therapy
Researchers sought to determine whether patients with B-ALL who progress after CAR-T therapy would have a poor prognosis.
Genetic Model Predicts Survival Outcome in Older Patients With AML Treated With Intensive Chemotherapy
Researchers sought to determine whether the ALFA decision tool would be able to determine the prognosis for older patients with AML treated with intensive chemotherapy.
CD70-Targeting CAR-T Cells Promising in Patients With Acute Myeloid Leukemia
Researchers sought to determine whether CD-70 targeting CAR-T therapy would be an effective therapeutic strategy in patients with AML.
Review of the Cardiovascular Risks of TKI Therapy for Chronic Myeloid Leukemia
Tyrosine kinase inhibitors have improved survival outcomes for patients with CML, but these agents also have a greater risk for adverse cardiovascular events.
Chemotherapy With Antisense Oligonucleotide Oblimersen Improves Disease Free Survival in Older Patients With AML
Researchers sought to determine whether the antisense oligonucleotide oblimersen can be added safely to conventional chemotherapy for older patients with AML.
Pirtobrutinib Demonstrates Favorable Efficacy in Patients With B-Cell Malignancies
Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
CD200 Overexpression in Acute Myeloid Leukemia: A Potential Target
Researchers sought to determine whether for CD200 expression in leukemia stem cells would be associated with acute myeloid leukemia and therefore be a target for treatment.
Antibody Responses After COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine the efficacy of the COVID-19 vaccine in patients with CLL.
Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records
Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.
CXCL12 Expression Predictor of Poor Prognosis in Acute Myeloid Leukemia
Researchers sought to determine whether CXCL12 expression would be a predictor of poor prognosis in patients with acute myeloid leukemia.
Researchers Seek to Assess Monthly Adherence to Oral Chemotherapy Agents in Chronic Myeloid Leukemia
Researchers seek to characterize adherence trajectories, determine how side effects or financial status influence adherence, assess how adherence effects clinical outcomes, and explore unique patient perspectives.
How to Manage Venetoclax Resistance in Chronic Lymphocytic Leukemia
Experts outline treatment options for patients with venetoclax resistance.
MAPK Pathway Linked to Resistance to Phosphatidylinositol 3-Kinase Inhibition in Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine whether activation of MAPK pathway genes may play a role in resistance to PI3K inhibitor therapy in patients with CLL.
Does Adding Leukopheresis to Treatment Improve Survival in Acute Myeloid Leukemia With Leukostasis?
A retrospective analysis sought to determine if adding leukapheresis would improve survival in AML patients with leukostasis.
Latest Cytogenetics of Pediatric Acute Myeloid Leukemia
Researchers sought to update the latest information about cytogenetics in pediatric patients with AML with a focus on de novo disease.
No Characteristic Differences Identified Between Late and Very Late Relapse Acute Lymphoblastic Leukemia
Researchers sought to determine the characteristic differences between LR and VLR in patients with ALL.
Differential Regulation of Cell Growth and Invasion Capacity by a Tumor Suppressor in Brain Cancer
Researchers sought to determine the role of PML in glioblastoma and whether this may be a therapeutic target.
Acute Myeloid Leukemia: What Your Patients Need to Know
Acute myeloid leukemia (AML) progresses more rapidly than other forms of leukemia. As such, if you or your patient are concerned they may have AML it is important to educate them on the symptoms and risk factors of the disease, as well as how to detect it and what treatments it could entail.
Registry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or Intolerant to Tyrosine Kinase Inhibitors
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
Immunotherapeutic Potential of RNA-Modifying Drugs and MicroRNAs in Acute Myeloid Leukemia
Researchers reviewed epitranscriptomics and the prospects of precision medicines that target AML-associated genes.
Therapeutic Drug Monitoring Improved Incidence of Pleural Effusion With Dasatinib for CP-CML
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Treatment Strategies and Challenges in Chronic Lymphocytic Leukemia
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
HDMTX Promising for Patients With Primary CNS Lymphoma Ineligible for Clinical Trials
Researchers compared outcomes in patients with PCNSL who did not meet clinical trial criteria with those of patients from a major multicenter clinical trial of PCNSL.
Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia
At 4 years, there was no significant difference in overall survival.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia Safe, Successful, Even Outside Clinical Trials
A retrospective study demonstrates that TKI therapy discontinuation occurs frequently and successfully both in clinical trials and in the general population.
JAK/STAT Inhibition May Be Promising in AF10-Rearranged Leukemia
Researchers sought to determine whether JAK1 inhibition would be a therapeutic target in patients with AF10-rearranged acute myeloid leukemia.
Gemtuzumab Ozogamicin Can Improve Outcomes in Pediatric KMT2A-Rearranged Acute Myeloid Leukemia
Gemtuzumab ozogamicin improved event-free survival and disease-free survival.
Phase 3 Trial Evaluates Inotuzumab Ozogamicin Plus Frontline Chemotherapy in B-Cell ALL
Investigators seek to evaluate how the addition of inotuzumab ozogamicin to frontline chemotherapy affects patients with newly diagnosed B-cell ALL.
CAR T Cell Therapy May Not Improve Survival vs Chemotherapy in B-ALL After Allo-HSCT
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Reducing Maintenance Produced ‘Outstanding’ Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia
Survival rates were similar whether maintenance was given every 12 weeks or every 4 weeks.
Transcranial Direct Current Stimulation in Adult Survivors of Pediatric Acute Lymphoblastic Leukemia
The primary outcome of the study is to evaluate the efficacy of home-based tDCS combined with remote cognitive training on direct testing of executive function in survivors of ALL.
Gene Mutations in IDH-Mutated Acute Myeloid Leukemia Have Prognostic Significance
Researchers sought to determine what genetic mutations may have prognostic significance for chemotherapy and stem cell transplant in patients with AML.
Integrated Palliative Care Improves Symptoms, Coping in Patients Hospitalized for Acute Myeloid Leukemia Treatment
Analysis findings that demonstrated the benefit of an integrated palliative care intervention for hospitalized patients with AML were presented at the 2021 ASCO Annual Meeting.
Umbralisib Shows Promise Among Patients With CLL Intolerant to BTK, PI3K Inhibitors
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
Leukemia-Specific T-Cells Promising for Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
Researchers sought to determine whether leukemia-specific T-cells would be a safe treatment for patients with AML or MDS after HSCT.
CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
Tisagenlecleucel Appears Effective in Babies With Advanced B-Cell Acute Lymphoblastic Leukemia
The 12-month overall survival rate was 88%.
Relapsed/Refractory, IDH2-Mutated AML: Olutasidenib Shows Promise
IDH1 differentiation syndrome of any grade was noted in 14% of patients, with 1 fatal case.
CML: COVID-19 May Be Fatal in More Than 5% of Patients
The mortality rate was 0.13% in the overall chronic myeloid leukemia cohort.
At-Home Chemotherapy Appears Safe, Feasible for Acute Myeloid Leukemia, Myelodysplastic Syndromes
Roughly a quarter of treatment cycles were administered solely as home-based treatment, with no hospital admissions required.
MEK Inhibitors May Overcome Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
New Prognostic Model for Patients With Acute Myeloid Leukemia With High-Risk Mutations
Researchers sought to identify a new model for predicting survival in patients with with acute myeloid leukemia.
Acalabrutinib May Reduce Toxicity in Chronic Lymphocytic Leukemia Compared With Ibrutinib
Researchers sought to determine whether acalabrutinib may lower the rate of treatment-related AEs while maintaining a similar PFS in patients with CLL.
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
High CMR Rates With Ponatinib Plus Blinatumomab in Adult Ph+ ALL
Although the standard of care for Ph+ ALL results in a 5-year overall survival of up to 50%, relapse is common and are frequently driven by the T3151 mutation in BCR-ABL.
Chronic Myeloid Leukemia: What Your Patients Need to Know
Chronic myeloid leukemia (CML) can be painful and life-threatening if it is not caught in time. How can you educate patients with symptoms or who are newly diagnosed about the detection, symptoms, risk factors, and treatment of CML?
Epigenetic Mutations Affect Acute Myeloid Leukemia Outcomes in Elderly Patients
Researchers sought to determine whether epigenetic mutations may affect AML outcomes in elderly patients, and how that can inform use of decitabine-based regimens.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Loading... 
Loading...